Pharmaceutical compositions comprising maralixibat and uses thereof
The invention relates to a pharmaceutical composition comprising maralixibat, or a pharmaceutically acceptable salt thereof, as the active ingredient. The invention further relates to the use of the pharmaceutical composition as a solid dosage drug product. The invention also relates to the use of the pharmaceutical composition and the solid dosage drug product described herein for treating cholestatic pruritus and cholestatic liver disease.
1. A pharmaceutical composition comprising maralixibat, or a pharmaceutically acceptable salt thereof, and:
(i) a diluent selected from the group consisting of dextrates, dextrin, dextrose, lactose, lactose monohydrate, mannitol, sorbitol, cellulose, modified celluloses, and any combination thereof;
(ii) a glidant selected from the group consisting of silicon dioxide, magnesium stearate, talc, and any combinations thereof;
(iii) a lubricant that is glyceryl palmitostearate in an amount of from about 6% to about 12% (w/w); and
(iv) a disintegrant selected from the group consisting of croscarmellose sodium, crospovidone, starch, sodium starch glycolate, and any combinations thereof in an amount of from about 1% to about 10% (w/w).
2. The composition of claim 1 , comprising maralixibat, or a pharmaceutically acceptable salt thereof, and:
(i) the diluent selected from the group consisting of dextrates, dextrin, dextrose, lactose, lactose monohydrate, mannitol, sorbitol, cellulose, modified celluloses, and any combination thereof;
(ii) the glidant selected from the group consisting of silicon dioxide, magnesium stearate, talc, and any combinations thereof in an amount of from about 0.1% to about 2% (w/w);
(iii) the lubricant that is glyceryl palmitostearate in an amount of from about 6% to about 12% (w/w); and
(iv) the disintegrant selected from the group consisting of croscarmellose sodium, crospovidone, starch, sodium starch glycolate, and any combinations thereof in an amount of from about 3% to about 7% (w/w).
3. The composition of claim 1 , wherein the composition is formulated as a solid dosage form.
4. The composition of claim 1 , wherein the composition is formulated as a capsule, a pill, a cachet, a tablet, a granule, a multi-particulate, a mini-tablet, or a powder.
5. The composition of claim 4 , wherein the composition is formulated as a tablet.
6. The composition of claim 1 , wherein the composition comprises from about 5 mg to about 50 mg of maralixibat or a pharmaceutically acceptable salt thereof based on the free base weight of maralixibat.
7. The composition of claim 1 , wherein the composition comprises from about 10% to about 25% (w/w) of maralixibat or a pharmaceutically acceptable salt thereof based on the free base weight of maralixibat.
8. The composition of claim 1 , wherein the composition comprises maralixibat chloride.
9. The composition of claim 1 , wherein the maralixibat, or a pharmaceutically acceptable salt thereof is loop milled or pin milled.
10. The composition of claim 1 , wherein the maralixibat, or a pharmaceutically acceptable salt thereof has a particle size distribution characterized by Dv90 of less than about 850 μm in diameter measured by laser diffraction.
11. The composition of claim 1 , wherein the maralixibat, or a pharmaceutically acceptable salt thereof has a particle size distribution characterized by Dv90 of less than about 100 μm in diameter measured by laser diffraction.
12. The composition of claim 1 , wherein:
a) the disintegrant is selected from the group consisting of croscarmellose sodium, crospovidone, and any combinations thereof;
b) the glidant is selected from the group consisting of silicon dioxide, talc, and any combinations thereof; and
c) the diluent is selected from the group consisting of lactose, lactose monohydrate, cellulose, modified celluloses, mannitol, and any combination thereof.
13. The composition of claim 12 , wherein:
a) the disintegrant is crospovidone,
b) the glidant is silicon dioxide, and
c) the diluent is selected from the group consisting of microcrystalline cellulose (MCC), lactose monohydrate, mannitol, and a combination thereof.
14. The composition of claim 1 , consisting of about 10.5% (w/w) of maralixibat chloride and
(i) about 50% (w/w) of MCC and about 25% (w/w) of lactose monohydrate;
(ii) about 0.5% (w/w) of silicon dioxide;
(iii) about 9% (w/w) of glyceryl palmitostearate; and
(iv) about 5% (w/w) of crospovidone.
15. The composition of claim 1 , consisting of about 9.8% (w/w) of maralixibat chloride and
(i) about 55.2% (w/w) of MCC and about 21.0% (w/w) of lactose monohydrate;
11 about 0.5% (w/w) of silicon dioxide;
(iii) about 8.6% (w/w) of glyceryl palmitostearate; and
(iv) about 5.0% (w/w) of crospovidone.
16. A method of preparing the pharmaceutical composition of claim 1 , comprising:
milling maralixibat, or a pharmaceutically acceptable salt thereof;
combining the milled maralixibat, or a pharmaceutically acceptable salt thereof, with the diluent, the glidant, the lubricant; and optionally the disintegrant to form an admixture; and
compacting the admixture to form the pharmaceutical composition.
17. A method of treating cholestatic pruritus in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 1 .
18. The method of claim 17 , wherein the cholestatic pruritus is associated with Alagille syndrome, wherein the subject has Alagille syndrome, wherein the subject is a pediatric subject between 2 months and 18 years of age, or wherein the subject is an adult who is 18 years of age or older.
19. A method of treating cholestatic liver disease or condition in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 1 .
20. The method of claim 19 , wherein the cholestatic liver disease or condition is selected from the group consisting of obstructive cholestasis, non-obstructive cholestasis, extrahepatic cholestasis, intrahepatic cholestasis, primary intrahepatic cholestasis, secondary intrahepatic cholestasis, progressive familial intrahepatic cholestasis (PFIC), PFIC type 1, PFIC type 2, PFIC type 3, PFIC type 4, PFIC type 5, PFIC type 6, benign recurrent intrahepatic cholestasis (BRIC), BRIC type 1, BRIC type 2, BRIC type 3, total parenteral nutrition associated cholestasis, paraneoplastic cholestasis, Stauffer syndrome, intrahepatic cholestasis of pregnancy, contraceptive-associated cholestasis, drug-associated cholestasis, infection-associated cholestasis, Dubin-Johnson Syndrome, primary biliary cirrhosis, primary sclerosing cholangitis, gallstone disease, Alagille syndrome, Dubin-Johnson Syndrome, biliary atresia, post-Kasai biliary atresia, post-liver transplantation biliary atresia, post-liver transplantation cholestasis, post-liver transplantation associated liver disease, intestinal failure associated liver disease, bile acid mediated liver injury, multidrug resistance-associated protein 2 (MRP2) deficiency syndrome, and neonatal sclerosing cholangitis.
21. An oral dosage form comprising from about 5 mg to about 50 mg of maralixibat, or a pharmaceutically acceptable salt thereof, based on the free base weight of maralixibat, and:
(i) a diluent selected from the group consisting of dextrates, dextrin, dextrose, lactose, lactose monohydrate, mannitol, sorbitol, cellulose, modified celluloses, and any combination thereof;
(ii) a glidant selected from the group consisting of silicon dioxide, magnesium stearate, talc, and any combinations thereof in an amount of from about 0.1% to about 2% (w/w);
(iii) a lubricant that is glyceryl palmitostearate in an amount of from about 6% to about 12% (w/w); and
(iv) a disintegrant selected from the group consisting of croscarmellose sodium, crospovidone, starch, sodium starch glycolate, and any combinations thereof in an amount of from about 3% to about 7% (w/w).
22. The dosage form of claim 21 , comprising about 10 mg or about 50 mg of maralixibat or a pharmaceutically acceptable salt thereof based on the free base weight of maralixibat.
23. The dosage form of claim 21 , wherein the dosage form does not comprise metal ions.
24. The dosage form of claim 21 , comprising from about 5 mg to about 50 mg of maralixibat, or a pharmaceutically acceptable salt thereof, based on the free base weight of maralixibat, and:
(i) the diluent that is selected from the group consisting of microcrystalline cellulose (MCC), lactose monohydrate, mannitol, and combinations thereof;
(ii) the glidant that is silicon dioxide in an amount of from about 0.1% to about 2% (w/w);
(iii) the lubricant that is glyceryl palmitostearate in an amount of from about 6% to about 12% (w/w); and
(iv) the disintegrant that is crospovidone in an amount of from about 3% to about 7% (w/w).
25. The dosage form of claim 21 , comprising about 50 mg of maralixibat, or a pharmaceutically acceptable salt thereof, based on the free base weight of maralixibat, and
(i) about 50% (w/w) of MCC and about 25% (w/w) of lactose monohydrate;
(ii) about 0.5% (w/w) of silicon dioxide;
(iii) about 9% (w/w) of glyceryl palmitostearate; and
(iv) about 5% (w/w) of crospovidone.
26. A method of treating cholestatic pruritus or a cholestatic liver disease or condition in a subject in need thereof, comprising administering to the subject the dosage form of claim 21 .
27. The method of claim 26 , wherein the cholestatic pruritus is associated with Alagille syndrome, wherein the subject has Alagille syndrome, wherein the subject is a pediatric subject between 2 months and 18 years of age, or wherein the subject is an adult who is 18 years of age or older.
28. The method of claim 27 , wherein the cholestatic liver disease or condition is selected from the group consisting of obstructive cholestasis, non-obstructive cholestasis, extrahepatic cholestasis, intrahepatic cholestasis, primary intrahepatic cholestasis, secondary intrahepatic cholestasis, progressive familial intrahepatic cholestasis (PFIC), PFIC type 1, PFIC type 2, PFIC type 3, PFIC type 4, PFIC type 5, PFIC type 6, benign recurrent intrahepatic cholestasis (BRIC), BRIC type 1, BRIC type 2, BRIC type 3, total parenteral nutrition associated cholestasis, paraneoplastic cholestasis, Stauffer syndrome, intrahepatic cholestasis of pregnancy, contraceptive-associated cholestasis, drug-associated cholestasis, infection-associated cholestasis, Dubin-Johnson Syndrome, primary biliary cirrhosis, primary sclerosing cholangitis, gallstone disease, Alagille syndrome, Dubin-Johnson Syndrome, biliary atresia, post-Kasai biliary atresia, post-liver transplantation biliary atresia, post-liver transplantation cholestasis, post-liver transplantation associated liver disease, intestinal failure associated liver disease, bile acid mediated liver injury, MRP2 deficiency syndrome, and neonatal sclerosing cholangitis.